Simultaneous Liver Transplant and Sleeve Gastrectomy: A Dual Approach to Combat Obesity and MASLD with Durable Outcomes
Posted inGastroenterology General Surgery news Transplantation

Simultaneous Liver Transplant and Sleeve Gastrectomy: A Dual Approach to Combat Obesity and MASLD with Durable Outcomes

Combining liver transplant with sleeve gastrectomy yields sustained weight loss, improved metabolic syndrome, and reduced liver allograft steatosis, without increasing mortality or graft loss, offering an effective treatment for obese patients with metabolic dysfunction-associated steatotic liver disease.
Everolimus and Low-Dose Tacrolimus Therapy After Pediatric Heart Transplant: Insights from a Multicenter Randomized Clinical Trial
Posted inCardiology Pediatrics Specialties Transplantation

Everolimus and Low-Dose Tacrolimus Therapy After Pediatric Heart Transplant: Insights from a Multicenter Randomized Clinical Trial

This randomized trial evaluates the safety and efficacy of everolimus combined with low-dose tacrolimus versus standard immunosuppression in children 6 months post-heart transplant, highlighting comparable rejection rates, improved kidney function, and reduced CMV infection risk.
Prolonged Hospitalization Post-Hematopoietic Cell Transplantation: Identifying Risk Factors and Impacts on Patient Outcomes
Posted inClinical Updates Hematology-Oncology Specialties Transplantation

Prolonged Hospitalization Post-Hematopoietic Cell Transplantation: Identifying Risk Factors and Impacts on Patient Outcomes

This study reveals that prolonged hospitalization after hematopoietic cell transplantation correlates with worse quality of life, greater symptom burden, increased depressive symptoms, and higher risk of rehospitalization and mortality within one year post-transplant.
Improving Outcomes in Mismatched Unrelated Donor Stem Cell Transplants With Post-Transplant Cyclophosphamide
Posted inClinical Updates Hematology-Oncology news Specialties Transplantation

Improving Outcomes in Mismatched Unrelated Donor Stem Cell Transplants With Post-Transplant Cyclophosphamide

Post-transplant cyclophosphamide (PTCy) for graft-versus-host disease prophylaxis significantly improves 1-year survival and lowers severe GVHD rates in mismatched unrelated donor peripheral blood stem cell transplants, expanding access for underrepresented patient groups.